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among patients receiving different HA treatments in a commercially-insured cohort 
of patients with knee OA. Methods: Retrospective analyses using IMS Health’s 
PharMetrics Plus Health Plan Claims Database were conducted by identifying knee 
OA patients with claims indicating initiation of HA treatment at an index date 
during the selection period (2007-2010). Patients were required to be continuously 
enrolled in the health claims database from 12-months pre-index to 36-months 
post. A generalized linear model (GLM) with a gamma distribution and log-link 
function was used to model aggregate patient-based changes in disease-specific 
costs. A Cox proportional hazards model (PHM) was used to model risk of TKR. Both 
multivariate models included covariates such as age, gender, comorbidities, and 
pre-index healthcare costs. Results: 50,389 patients with HA treatment for knee 
OA were identified. 18,217 (36.2%) patients received Supartz/Hyalgan (shared HCPCS 
code), 20,518 (40.7%) Synvisc, 6,263 (12.4%) Euflexxa, and 5,391 (10.7%) Orthovisc. 
Synvisc and Orthovisc patients showed more disease-specific costs compared to 
Supartz/Hyalgan (8.9% (p< 0.0001) and 6.8% (p= 0.0048) increase respectively). This 
implies that if users of Synvisc and Orthovisc with average disease-specific costs 
of $14,959 and $14,224 switch to Supartz/Hyalgan, they can save $1,223 and $906 
over 3 years respectively. Hazard ratios showed a significantly higher risk of TKR 
for patients receiving Synvisc compared to Supartz/Hyalgan (6.9% increase in haz-
ard (p= 0.0009)). Patients treated with Supartz/Hyalgan, Euflexxa and Orthovisc had 
longer delays of TKR. ConClusions: Multivariate statistical modeling showed that 
Supartz/Hyalgan represents a cost-effective alternative for providers. Both HAs 
reduce disease-specific costs and delay TKR when compared to other products.
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objeCtives: Approximately 80% of US hemodialysis patients initiate dialysis with 
a central venous catheter (CVC) despite their high incidence of infections compared 
to other vascular access modalities (USRDS 2011). Early cannulation arteriovenous 
grafts (ecAVGs) can be cannulated within 24 hours of implantation thus minimizing 
the dependency on CVCs compared to non-ecAVGs. We compare CVC sepsis costs for 
patients implanted with ecAVGs to those with non-ecAVGs. Methods: An economic 
model was estimated using the GORE® ACUSEAL Vascular Graft (GAVG) Clinical Study 
(Clinicaltrials.gov NCT01173718), clinical literature, and publicly available cost sources. 
The GAVG study was a prospective, multi-center, single-arm study to establish the 
safety and efficacy of the GAVG for use in hemodialysis access. The study collected 
data on the first three consecutive hemodialysis sessions, which is a surrogate end-
point for time to potential CVC removal. The median days to potential CVC removal 
was 15.5 compared to an average of 34 days for non-ecAVGs from Quinn (2009) and 
Shingarev et al. (2011). CVC sepsis rates of 2.32 per patient-year were obtained from 
the US Renal Data System (2011). The CVC sepsis hospitalization cost was calculated 
as $27,088 (2014 dollars) from HCUP NIS (2010). Results: Assuming 100 patients in 
each group, the ecAVG group was estimated to have 9.9 CVC sepsis episodes com-
pared to 21.6 in the non-ecAVG group, with estimated sepsis hospitalization costs 
of $268,171 versus $585,100, respectively, due to the extended time on the CVC. The 
ecAVG potentially reduces CVC sepsis episodes by 11.7 since it reduces the number 
of catheter-dependent days by 18.5 compared to the non-ecAVG. On a per patient 
basis, the estimated average CVC sepsis costs in the ecAVG group were $2,682/patient 
versus $5,851/patient in the non-ecAVG group, resulting in a cost savings of $3,189/
patient. ConClusions: It is estimated ecAVGs reduce overall CVC sepsis costs com-
pared to non-ecAVGs due to fewer CVC-dependent days.
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objeCtives: Manual suturing is currently used to perform ileocolic anastomosis in 
colorectal surgery. Because of its documented post-surgical complications shown 
in literature (anastomotic leaks and reoperations), alternative techniques such as 
mechanical stapling might yield clinical and economic benefits for hospitals. The 
objective of this study was to estimate the economic impact derived from the use of 
mechanical stapling and handsewn techniques in open ileocolic anastomoses from 
a Mexican public hospital perspective (IMSS). Methods: An Excel-based decision 
tree model was used to compare clinical and economic outcomes of both anasto-
moses techniques. Data for anastomotic leak and reoperation rates for mechanical 
and handsewn suturing were taken from international published literature. Given 
procedure volume variability in comparable hospitals, base-case scenario assumed 
100 annual procedures with each anastomosis technique. Considered complications 
were anastomotic leak (requiring readmission) and reoperation due to fistuliza-
tion and anastomotic stricture. Stapler, cutter and traditional suture utilization 
patterns were based on expert opinions, while their unitary costs were provided 
by internal resources. Inflation-adjusted DRGs from IMSS´s second level hospitals 
were used as hospitalization, readmission and reoperation costs. Results are shown 
in 2015-adjusted USD; considered time horizon was < 1 year, thus no discount rate 
for costs was necessary. Results: Stapled colorectal anastomoses resulted in a 
significant reduction in anastomotic leaks and reoperations compared to handsewn 
technique. Net potential savings due to avoided readmissions and reoperations with 
mechanical stapler accounted for $32,422 and $197,992 respectively; net saving per 
patient was $1,784. ConClusions: The use of stapling devices to perform ileocolic 
anastomosis can yield potential clinical and economic benefits due to the reduction 
of readmission and reoperation rates. Local public healthcare institutions should 
consider the adoption of mechanical stapling techniques in colorectal surgery as it 
appears to be a cost saving alternative.
appropriate care when the blood-based EGFR mutation testing was used as an alter-
native test to tissue-based EGFR mutation testing alone (93% vs 90%, respectively). 
As a result of increased diagnostic yield, there was a 23% decrease in cost per 
NSCLC patient per month compared to tissue-based testing alone ($1,665 vs $1,265). 
Costs per NSCLC patient per month are similar when blood-based testing is used 
in place of CT scan for ongoing monitoring of tumor progression. ConClusions: 
The blood-based cobas® EGFR Mutation Test has advantages for patient outcomes 
when performed as an alternative test to tissue-based testing when tissue sample 
is not available or when used as an ongoing monitoring tool for tumor progres-
sion. By correctly identifying more patients for proper treatment, the blood-based 
test represents a good alternative to tissue-based testing for identification of EGFR 
mutations in locally advanced or metastatic NSCLC patients.
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objeCtives: Advances in molecular diagnostics for the detection of disease can pro-
vide opportunities for healthcare providers to intervene earlier and subsequently, 
improve outcomes. Payers are increasingly focused on assessing the cost and over-
all value of such tools. The kSORT assay is a non-invasive test that can be used 
as a screening tool to detect subclinical rejection (SCR) among kidney transplant 
patients. The current standard of care may consist of routine screening for clini-
cal acute rejection (AR) or the use of invasive surveillance biopsies to detect SCR 
through histologic diagnosis. Preliminary data show that the k-SORT assay performs 
as well as and potentially superior to biopsies for the detection of SCR and prediction 
of AR. The objective of this analysis is to evaluate the potential budget impact of 
the kSORT assay from a commercial payer perspective using a set of conservative 
assumptions. Methods: A 2-year Markov model incorporating SCR, AR, and graft 
failure was developed to evaluate the budget impact from a U.S. commercial payer 
perspective of the k-SORT assay among patients with incident kidney transplants. 
Probabilities for progression were obtained by calibrating the values to correspond 
with reported prevalence rates of SCR and incidence rates of AR from published 
registry data. Costs were obtained through the peer-reviewed literature and sensitiv-
ity analyses were performed. Results: Across a set of conservative assumptions, 
use of the kSORT assay may have a minimal budget impact (< $0.05) PMPM across 
most scenarios. Key value drivers include the frequency of monitoring, costs of 
the assay, and concurrent use of protocol biopsies with the assay. ConClusions: 
The use of k-SORT to detect SCR is likely to produce a minimal budget impact for 
commercial payers. Additional studies demonstrating the clinical performance of 
the assay compared to biopsies can help to provide further insight into the clinical 
and economic benefits.
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objeCtives: Hypoglycemic events (HEs) are important acute complications in 
patients with diabetes mellitus, especially insulin-treated. Severe HEs (sHEs) cause 
high treatment costs and have a major impact on patients’ quality of life. A newly 
available, innovative blood glucose measurement device (IBGMD), using a technology 
identifying patterns of low blood glucose and alerting the patient about a potential 
sHE (“pattern alert technology”, PAT), is studied to determine (i) the number of avoid-
able sHEs through deployment of IBGMD using PAT, compared to a conventional 
blood glucose measurement device (CBGMD), (ii) the IBGMD net cost, and (iii) its 
impact on overall management costs. Methods: Values attached to epidemiologic, 
cost and behavioral input variables were taken from scientific literature and authori-
tative sources. A decision-analytic, one-year model comparing direct costs (payer 
perspective) and sHE outcomes between IBGMD and CBGMD was developed, and 
budget impact and cost-effectiveness calculations were performed, reflecting the 
US insulin-treated diabetic population. Results: On an overall population level, 
in the base-case scenario (sHE incidence 8.99%, PAT compliance 90%), usage of the 
IBGMD could lead to an extra 92,181 avoided sHEs annually, compared to a CBGMD. 
Assuming price parity of test strips across both devices ($0.21/strip at Medicare 
price $10.40 per 50-unit pack), its implementation is cost-neutral. At an average 
treatment cost of $7,598 per single sHE, this would lead to overall net cost savings 
of over $700 million per year. In alternative scenarios, achievable savings range 
from $103.7 million to nearly $6.7 billion per year. In terms of incremental cost-
effectiveness, IBGMD is considered dominant, as it features higher effectiveness 
(extra sHEs avoided) at lower overall costs compared to a CBGMD. ConClusions: 
An innovative blood glucose measurement device with pattern alert technology 
can avoid a sizeable number of sHEs and may lead to considerable cost savings, if 
implemented widely in the target population.
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objeCtives: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis 
(OA) effectively reduces pain and delays total knee replacement (TKR) surgery; how-
ever, little is known about relative differences in clinical and cost outcomes among 
different HA products. We aimed to compare disease-specific costs and risk of TKR 
